TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology | June 09, 2017
June 5, 2017 – The U.S. Food and Drug Administration (FDA) granted market clearance for the Claret Medical Sentinel ...
Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology | June 06, 2017 | Dave Fornell
June 6, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-in-...
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology | May 31, 2017
May 31, 2017 — LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety...
The Boston Scientific Lotus TAVR Valve
Feature | Heart Valve Technology | May 25, 2017
May 25, 2017 — Positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology | May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for transcatheter...
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab | May 23, 2017
May 23, 2017 — Shockwave Medical announced last week CE mark for the company’s Coronary Lithoplasty System for the...
FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc. AC3 Optimus...
a list of SCAI late breaking trial presentations
Feature | SCAI | May 01, 2017
May 30, 2017 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions took place...
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices | April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment...
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation | March 31, 2017
March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side...
Videos | Stents Bioresorbable | March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses the...
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology | March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic...
Medtronic Corevalve Evolut Pro, TAVR system
Feature | Heart Valve Technology | March 22, 2017
March 22, 2017 – The U.S. Food and Drug Administration (FDA) and granted market clearance to the Medtronic CoreValve...
RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots...
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable | March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiology...